[Combined treatment for malignant tumors using focal ethanol injections].
The potential of focal ethanol injection therapy (FEIT) as a component of combined treatment for malignant tumors was investigated. Thirty-four patients with inoperable primary and recurrent liver cancer received 72 FEIT procedures at the Institute's Clinic - 16 males (47%) and 18 females (53%), aged 35-80, (average 57), (1991-2004). Forty-three metastatic foci - colorectal carcinoma (23), non-colorectal carcinoma (20) and hepatocellular carcinoma (11) - were detected. Size of metastatic foci ranged 3.2-27.8 cm3 (average 15.4+/-6.4 cm3), while those of hepatocellular carcinoma - 156.7-982.4 cm3, (average 492.4+/-136.8 cm3). All patients received regional endovascular chemotherapy, without any life-threatening complications. Reduction in focal size after FEIT for hepatocellular carcinoma ranged 490.2+/-136.8 - 41.8+/-14 cm3. One-, three- and five-year survival was 100, 80 and 60%, respectively. In cases of hepatocellular carcinoma, ethanol-treated foci shrank by 88.4% - from 15.5+/-1.6 to 1.8 +/- 0.3 cm3 (p<0.05). One-, and three-year survival rates were 83 and 14%, respectively. After ethanol ablation, size of metastatic foci fell by 79%, from 13.9+/-4.3 to 2.9+/-2.4 cm3 (p<0.05). One- and three-year survival rates were 91 and 13%, respectively.
Veriasova
N N
NN
Polysalov
V N
VN
Ivanova
A A
AA
Krotova
O A
OA
Urbanskiĭ
A I
AI
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000473:pathology / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D015179:Colorectal Neoplasms / Q000473:pathology; D000431:Ethanol / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D015552:Injections, Intralesional; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012597:Sclerosing Solutions / Q000008:administration & dosage*; D015911:Sclerotherapy / Q000379:methods*; D016019:Survival Analysis; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D012597:Sclerosing Solutions; D000431:Ethanol